The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1483, Issue 2, 2000, Pages 285-293

  Abramovitz, Mark ^a   Adam, Mohammed ^a   Boie, Yves ^a   Carrière, Marie Claude ^a   Denis, Danielle ^a   Godbout, Claude ^a   Lamontagne, Sonia ^a   Rochette, Chantal ^a   Sawyer, Nicole ^a   Tremblay, Nathalie M ^a   Belley, Michel ^a   Gallant, Michel ^a   Dufresne, Claude ^a   Gareau, Yves ^a   Ruel, Rejean ^a   Juteau, Helene ^a   Labelle, Marc ^a   Ouimet, Nathalie ^a   Metters, Kathleen M ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Human embryonic kidney cell line; Prostaglandin; Prostaglandin analog; Prostanoid receptor; Radioligand binding; Recombinant

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANORPROSTAGLANDIN F2 ALPHA; BUTAPROST; CARBACYCLIN; CLOPROSTENOL; ENPROSTIL; FLUPROSTENOL; GR 63799; ILOPROST; LATANOPROST; MISOPROSTOL; MISOPROSTOL METHYL ESTER; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID RECEPTOR; RECOMBINANT RECEPTOR; SC 51089; SC 51322; SULPROSTONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL LINE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; PRIORITY JOURNAL; RECEPTOR BINDING;

BINDING, COMPETITIVE; CELL LINE; CELL MEMBRANE; HUMANS; LIGANDS; PROSTAGLANDINS; RADIOLIGAND ASSAY; RECEPTORS, PROSTAGLANDIN; RECOMBINANT PROTEINS;

EID: 0033971515     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-1981(99)00164-X     Document Type: Article

References (23)

1. Funk C.D., Furci L., Fitzgerald G.A., Grygorczyk R., Rochette C., Bayne M.A., Abramovitz M., Adam M., Metters K.M. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. 268:1993;26767-26772.
2. Regan J.W., Bailey T.J., Pepperi D.J., Pierce K.L., Bogardus A.M., Donello J.E., Fairbairn C.E., Kedzie K.M., Woodward D.F., Gil D.W. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol. 46:1994;213-220.
3. Adam M., Boie Y., Rushmore T.H., Muller G., Bastien L., McKee K.T., Metters K.M., Abramovitz M. Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett. 338:1994;170-174.
4. Bastien L., Sawyer N., Grygorczyk R., Metters K.M., Adam M. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J. Biol. Chem. 269:1994;11873-11877.
5. Abramovitz M., Boie Y., Nguyen T., Rushmore T.H., Bayne M.A., Metters K.M., Slipetz D.M., Grygorczyk R. Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 269:1994;2632-2636.
6. Boie Y., Sawyer N., Slipetz D.M., Metters K.M., Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270:1995;18910-118916.
7. Boie Y., Rushmore T.H., Darmon-Goodwin A., Grygorczyk R., Slipetz D.M., Metters K.M., Abramovitz M. Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem. 269:1994;12173-12178.
8. Hirata M., Hayashi Y., Ushikubi F., Yokota Y., Kageyama R., Nakanishi S., Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 349:1991;617-620.
9. Schmid A., Thierauch K.-H., Schleuning W.-D., Dinter H. Splice variants of the Human EP3 Receptor for Prostaglandin E2. Eur. J. Pharmacol. 228:1995;23-30.
10. Raychowdhury M.K., Yukawa M., Collins L.J., McGrail S.H., Kent C., Ware J.A. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J. Biol. Chem. 269:1994;19256-19261.
11. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S. Ligand binding specificies of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122:1997;217-224.
12. Feldman H.A. Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting. Anal. Biochem. 48:1972;317-338.
13. Wright D.H., Metters K.M., Abramovitz M., Ford-Hutchinson A.W. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br. J. Pharmacol. 123:1998;1317-1324.
14. 3 receptor with different carboxyl-terminal domains. J. Biol. Chem. 268:1993;2712-2718.
15. 3 subtype with guanine nucleotide-binding proteins, showing low-affinity ligand binding. Biochim. Biophys. Acta. 1175:1993;343-350.
16. 3 subtype is essential for activation of GTP-binding protein. Eur. J. Biochem. 224:1994;161-166.
17. R.A. Coleman, L. Kennedy, P.P.A. Humphrey, K. Bunce, P. Lumley, Prostanoids and their receptors, in: C. Hansch, P.G. Sammea, J.B. Taylor, J.C. Emmett (Eds.), Comprehensive Medicinal Chemistry, Vol. 3, Pergamon Press, Oxford, pp. 643-714.
18. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
19. 2 antagonist and analgesic. Bioorg. Med. Chem. Lett. 3:1994;509-514.
20. 2 antagonists, J. Med. Chem. 36 (1993) 3293-3299.
21. 2 receptor antagonist. Biochem. Pharmacol. 50:1995;1731-1733.
22. Higginbotham E.J. Will latanoprost be the 'wonder' drug of the '90's for the treatment of glaucoma? Arch. Ophthalmol. 114:1996;998-999.
23. Bito L.Z., Stjernschantz J., Resul B., Miranda O.C., Basu S. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management. J. Lipid Med. 6:1993;535-543.